JPWO2020146521A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146521A5 JPWO2020146521A5 JP2021540037A JP2021540037A JPWO2020146521A5 JP WO2020146521 A5 JPWO2020146521 A5 JP WO2020146521A5 JP 2021540037 A JP2021540037 A JP 2021540037A JP 2021540037 A JP2021540037 A JP 2021540037A JP WO2020146521 A5 JPWO2020146521 A5 JP WO2020146521A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai agent
- nucleotide
- nucleotides
- modified
- sense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000025458 RNA interference Effects 0.000 claims 29
- 239000003795 chemical substances by application Substances 0.000 claims 28
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 239000002773 nucleotide Substances 0.000 claims 16
- 229920000972 Sense strand Polymers 0.000 claims 15
- 230000000692 anti-sense Effects 0.000 claims 14
- 230000027455 binding Effects 0.000 claims 9
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 7
- 239000003446 ligand Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 102100016168 EPAS1 Human genes 0.000 claims 5
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims 5
- 230000000275 pharmacokinetic Effects 0.000 claims 5
- 230000000295 complement Effects 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 4
- 230000002708 enhancing Effects 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010057190 Respiratory tract infection Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 206010049460 Abasia Diseases 0.000 claims 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N Ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N Ribitol Natural products OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 1
- 239000002214 arabinonucleotide Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001921 locked nucleotide group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000003278 mimic Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962790360P | 2019-01-09 | 2019-01-09 | |
| US62/790,360 | 2019-01-09 | ||
| US201962827564P | 2019-04-01 | 2019-04-01 | |
| US62/827,564 | 2019-04-01 | ||
| US201962839381P | 2019-04-26 | 2019-04-26 | |
| US62/839,381 | 2019-04-26 | ||
| PCT/US2020/012775 WO2020146521A2 (en) | 2019-01-09 | 2020-01-08 | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022518384A JP2022518384A (ja) | 2022-03-15 |
| JPWO2020146521A5 true JPWO2020146521A5 (zh) | 2023-01-20 |
Family
ID=71520182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540037A Pending JP2022518384A (ja) | 2019-01-09 | 2020-01-08 | ＨＩＦ－２アルファ（ＥＰＡＳ１）の発現を阻害するためのＲＮＡｉ剤、その組成物及び使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220204976A1 (zh) |
| EP (1) | EP3908288A4 (zh) |
| JP (1) | JP2022518384A (zh) |
| KR (1) | KR20210113273A (zh) |
| CN (1) | CN113613661A (zh) |
| AU (1) | AU2020207050A1 (zh) |
| BR (1) | BR112021013362A2 (zh) |
| CA (1) | CA3120580A1 (zh) |
| IL (1) | IL284696A (zh) |
| MX (1) | MX2021008261A (zh) |
| SG (1) | SG11202105577TA (zh) |
| TW (1) | TW202043470A (zh) |
| UY (1) | UY38539A (zh) |
| WO (1) | WO2020146521A2 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114053426B (zh) * | 2020-07-30 | 2024-06-18 | 成都科岭源医药技术有限公司 | 一种双药链接组装单元及双药靶向接头-药物偶联物 |
| CN116323633A (zh) * | 2020-09-11 | 2023-06-23 | 箭头药业股份有限公司 | 骨骼肌递送平台及使用方法 |
| WO2022086882A1 (en) | 2020-10-21 | 2022-04-28 | Nikang Therapeutics, Inc. | Diagnostic and therapeutic methods for treatment of cancer with a hif-2(alpha) inhibitor |
| CN115105607A (zh) * | 2021-03-22 | 2022-09-27 | 成都科岭源医药技术有限公司 | 一种用于adc的双药-接头的制备方法及其用途 |
| CN113304274A (zh) * | 2021-04-23 | 2021-08-27 | 南开大学 | 缀合物及其制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2268317T3 (da) * | 2008-03-14 | 2020-05-25 | Visen Medical Inc | Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme |
| AU2009232355A1 (en) * | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of EPAS1 inhibitors |
| SG10201706960TA (en) * | 2013-02-28 | 2017-10-30 | Arrowhead Res Corp | Organic compositions to treat epas1-related diseases |
| CN114601845A (zh) * | 2015-05-29 | 2022-06-10 | 箭头药业股份有限公司 | 抑制Hif2α基因表达的组合物及方法 |
-
2020
- 2020-01-08 SG SG11202105577TA patent/SG11202105577TA/en unknown
- 2020-01-08 KR KR1020217024646A patent/KR20210113273A/ko unknown
- 2020-01-08 AU AU2020207050A patent/AU2020207050A1/en not_active Abandoned
- 2020-01-08 CN CN202080008795.4A patent/CN113613661A/zh active Pending
- 2020-01-08 MX MX2021008261A patent/MX2021008261A/es unknown
- 2020-01-08 BR BR112021013362A patent/BR112021013362A2/pt not_active Application Discontinuation
- 2020-01-08 CA CA3120580A patent/CA3120580A1/en active Pending
- 2020-01-08 JP JP2021540037A patent/JP2022518384A/ja active Pending
- 2020-01-08 EP EP20738972.7A patent/EP3908288A4/en active Pending
- 2020-01-08 WO PCT/US2020/012775 patent/WO2020146521A2/en unknown
- 2020-01-08 US US17/420,460 patent/US20220204976A1/en active Pending
- 2020-01-09 UY UY0001038539A patent/UY38539A/es unknown
- 2020-01-09 TW TW109100806A patent/TW202043470A/zh unknown
-
2021
- 2021-07-07 IL IL284696A patent/IL284696A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102208588B1 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| JP2018529732A5 (zh) | ||
| JP2022062143A (ja) | 腎臓病の処置のための組成物と方法 | |
| JP2016520312A5 (zh) | ||
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| JP2009159971A5 (zh) | ||
| JP2014518612A5 (zh) | ||
| JP2014527401A5 (zh) | ||
| JP6847852B2 (ja) | 癌治療のためのヒト抗原Ｒ発現のｓｉＲＮＡ阻害 | |
| JP2013537404A5 (zh) | ||
| KR20150006742A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
| JPWO2020146521A5 (zh) | ||
| JP2023531249A (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| JP2023506546A (ja) | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 | |
| JP7464709B2 (ja) | Ｃｔｇｆ遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物 | |
| WO2024162453A1 (ja) | 一本鎖核酸及びその用途 | |
| WO2024212954A1 (zh) | 抑制lpa基因表达的化合物、药物组合物及其用途 | |
| TW202309286A (zh) | 作為新穎基因靜默技術的非對稱短雙股ｄｎａ及其應用 | |
| TW202313977A (zh) | 作為新穎基因靜默技術的短雙股ｄｎａ及其應用 |